Biopharma's
Public Probability
The State and Future of Prediction Markets in Drug Development
Read the ReportDisclosure
AppliedXL has a commercial relationship with Kalshi. As part of that partnership, AppliedXL provides resolution for biopharma markets. It also independently collaborates on research that is clearly marked as such. News coverage is generated independently by AppliedXL’s editorial systems and is not reviewed, influenced, or approved by Kalshi.
The Phase 3 PROTEUS trial met both co-primary endpoints, with perioperative apalutamide lowering metastasis-free survival risk by 20% ahead of the trial's December 2026 completion date.
The ECOG-ACRIN Phase 3 trial found near-identical seven-year survival with fixed two-year lenalidomide versus indefinite therapy, while indefinite dosing carried more toxicity and second cancers.
Powered by the AppliedXL resolution platform. Referral fees may apply.Learn more.
FDA decision deadlines, pivotal trial readouts, and conference presentations.
BIOTECH AGENTThe predictive platform for clinical readouts, results, and real-time monitoring, powered by state-of-the-art forecasting models.
Everything on this page is powered by the AppliedXL intelligence engine. The catalysts, probability scores, and resolved outcomes you're seeing are generated live from the public clinical-trial record. The same infrastructure powers products for leading platforms and information companies.
